InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-8.1%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Enyedy Mark J, Chief Executive Officer. Officer active across 3 companies, notably ImmunoGen, Inc.. Cumulatively, 12 disclosures have been recorded. Activity tracked since 30 June 2021. The latest transaction was disclosed on 2 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
7,490 shares0Common StockSEC:0001628280-26-040914:0
6,650 shares0Common StockSEC:0001048477-25-000070:0
4,720 shares0Common StockSEC:0001048477-24-000100:0
584,397 sharesCommon StockSEC:0001104659-24-014715:0
51,234 shares0Common StockSEC:0001415889-24-002871:0
2,180 shares0Common StockSEC:0001048477-23-000072:0
995,157 shares@ US$4.5598.4% of flowCommon StockSEC:0001415889-23-011881:0
5,241 shares@ US$4.050.5% of flowCommon StockSEC:0001415889-23-010830:0
2,921 sharesCommon StockSEC:0000899243-22-036305:0
3,342 shares@ US$3.8250.3% of flowCommon StockSEC:0001415889-22-007327:0
3,849 shares@ US$5.5250.0% of flowCommon StockSEC:0001179110-21-007317:0
3,849 shares@ US$5.520.4% of flowCommon StockSEC:0001179110-21-007317
12 of 12 declarations
About Enyedy Mark J
Mark J. Enyedy is the Chief Executive Officer of ImmunoGen, Inc. He is responsible for the strategic direction and management of the company's operations. His leadership is essential in ensuring growth and innovation at ImmunoGen.
